Patents by Inventor Scott L. Harbeson

Scott L. Harbeson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
    Publication number: 20120004236
    Abstract: This invention relates to novel substituted triazolo-pyridazines, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?1-GABA-A receptor antagonist and/or a ?2, ?3 and ?5 GABA-A receptor agonist.
    Type: Application
    Filed: June 30, 2011
    Publication date: January 5, 2012
    Applicant: Concert Pharmaceuticals Inc.
    Inventor: Scott L. Harbeson
  • DEUTERATED PYRIDINONES
    Publication number: 20110313004
    Abstract: This invention relates to novel substituted pyridinones, their deuterium-modified derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a TNF (tumor necrosis factor) alpha production inhibitor/TGF (transforming growth factor) beta inhibitor.
    Type: Application
    Filed: December 3, 2009
    Publication date: December 22, 2011
    Applicant: CONCERT PHARMACEUTICALS, INC.
    Inventor: Scott L. Harbeson
  • Endothelin receptor antagonists
    Patent number: 8080549
    Abstract: This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway that leads to vasoconstriction and in particular those diseases or conditions beneficially treated by endothelin receptor antagonists.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: December 20, 2011
    Assignee: CoNCERT Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Endothelin receptor antagonists
    Patent number: 8071596
    Abstract: This invention relates to novel endothelin receptor antagonists, derivatives, acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by compounds that block the endothelin signaling pathway that leads to vasoconstriction and in particular those diseases or conditions beneficially treated by endothelin receptor antagonists.
    Type: Grant
    Filed: January 11, 2008
    Date of Patent: December 6, 2011
    Assignee: CoNCERT Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • PROSTACYCLIN ANALOGS
    Publication number: 20110294815
    Abstract: This invention relates to novel prostacyclin analogs and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel prostacyclin analogs that are derivatives of treprostinil. This invention also provides compositions comprising a compound of this invention and a carrier and the use disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering analogues of prostacyclin, such as treprostinil.
    Type: Application
    Filed: June 26, 2009
    Publication date: December 1, 2011
    Inventor: Scott L. Harbeson
  • Hydroxyethlamino Sulfonamide Derivatives
    Publication number: 20110257111
    Abstract: This invention relates to novel hydroxyethylamino sulfonamides and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as an HIV (human immunodeficiency virus) protease inhibitor.
    Type: Application
    Filed: October 23, 2009
    Publication date: October 20, 2011
    Inventors: Scott L. Harbeson, Carig E. Masse
  • 4-oxoquinoline derivatives
    Patent number: 7994194
    Abstract: This invention relates to novel compounds that are 4-oxoquinoline derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel 4-oxoquinoline derivatives that are derivatives of elvitegravir. This invention also provides pyrogen-free compositions comprising one or more compounds of this invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an HIV integrase inhibitor, such as elvitegravir.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: August 9, 2011
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • Substituted Benzimidazoles
    Publication number: 20110172280
    Abstract: This invention relates to novel substituted benzimidazoles and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound that modulates the GABAA receptor. This invention also provides novel intermediates for the preparation of the compounds of the invention, and salts thereof.
    Type: Application
    Filed: October 15, 2010
    Publication date: July 14, 2011
    Applicant: CoNCERT Pharmaceuticals, Inc.
    Inventors: Julie F. Liu, Scott L. Harbeson
  • SUBSTITUTED TRIAZOLOPHTHALAZINE DERIVATIVES
    Publication number: 20110172235
    Abstract: This invention relates to novel substituted triazolophthalazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering selective ?5 receptor partial or full inverse agonists.
    Type: Application
    Filed: August 13, 2010
    Publication date: July 14, 2011
    Applicant: CoNCERT Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson
  • DEUTERATED TIZANIDINE
    Publication number: 20110160253
    Abstract: This disclosure relates to novel benzothiadiazoles, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?2-adrenoceptor agonist.
    Type: Application
    Filed: May 27, 2009
    Publication date: June 30, 2011
    Inventor: Scott L. Harbeson
  • Anti-anginal compounds
    Patent number: 7943620
    Abstract: This invention relates to novel compounds that partially inhibit fatty acid oxidation and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel compounds that are derivatives of ranolazine. This invention also provides compositions comprising one or more compound of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by partial fatty acid oxidation inhibitors, such as ranolazine.
    Type: Grant
    Filed: March 7, 2008
    Date of Patent: May 17, 2011
    Assignee: Concert Pharmaceuticals, Inc.
    Inventors: Scott L. Harbeson, Craig Masse
  • DEUTERIUM BEARING ANALOGS OF ANASTROZOLE AS AROMATASE INHIBITORS FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20110104158
    Abstract: This invention relates to novel, substituted aralkyl heterocyclic compounds according to formula I, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering aromatase inhibitors. Formula (I), or a pharmaceutically acceptable salt thereof, wherein: each R1 is independently selected from CH3, CH2D, CHD2 or CD3; each R2 is independently selected from CH3, CH2D, CHD2 or CD3; each Y is independently selected from H or D; and when each R variable is CH3, at least one Y is D.
    Type: Application
    Filed: April 15, 2009
    Publication date: May 5, 2011
    Inventor: Scott L. Harbeson
  • SUBSTITUTED IMIDAZOTRIAZINES
    Publication number: 20110082147
    Abstract: This invention relates to novel substituted imidazotriazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound showing partial-agonist activity at the GABA ?2, ?3 and ?5 subtype receptors, and antagonist activity at the al subtype receptor.
    Type: Application
    Filed: July 23, 2010
    Publication date: April 7, 2011
    Applicant: CoNCERT Pharmaceuticals, Inc.
    Inventors: Scott L. Harbeson, Roger D. Tung, Julie F. Liu
  • SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20110077255
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Application
    Filed: September 2, 2010
    Publication date: March 31, 2011
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
    Publication number: 20110065711
    Abstract: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?1-GABAA receptor antagonist or an ?2- and/or an ?3-GABAA receptor partial agonist.
    Type: Application
    Filed: June 22, 2010
    Publication date: March 17, 2011
    Applicant: CoNCERT Pharmaceuticals, Inc.
    Inventors: Scott L. Harbeson, Roger D. Tung, Julie F. Liu
  • SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20110059995
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Application
    Filed: September 1, 2010
    Publication date: March 10, 2011
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • SUBSTITUTED XANTHINE DERIVATIVES
    Publication number: 20110053961
    Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.
    Type: Application
    Filed: September 1, 2010
    Publication date: March 3, 2011
    Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
  • Azapeptide Derivatives
    Publication number: 20110009355
    Abstract: This invention relates to novel compounds that are azapeptides, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel azapeptide compounds that are derivatives of the HIV protease inhibitor atazanavir sulfate. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering HIV protease inhibitors. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving atazanavir.
    Type: Application
    Filed: April 6, 2010
    Publication date: January 13, 2011
    Inventors: Scott L. Harbeson, Roger D. Tung
  • HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES
    Publication number: 20100305173
    Abstract: This invention relates to novel hydroxyethylamino sulfonamides, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as an HIV (human immunodeficiency virus) protease inhibitor.
    Type: Application
    Filed: April 30, 2010
    Publication date: December 2, 2010
    Applicant: CoNCERT Pharmaceuticals, Inc.
    Inventors: Scott L. Harbeson, Roger D. Tung, Julie F. Liu, Craig E. Masse
  • Tetrahydrotriazolopyrazine derivatives and uses thereof
    Patent number: 7820666
    Abstract: This invention relates to novel substituted tetrahydrotriazolopyrazines and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an enzyme inhibitor of dipeptidyl-peptidase IV (DPP-IV).
    Type: Grant
    Filed: May 7, 2008
    Date of Patent: October 26, 2010
    Assignee: Concert Pharmaceuticals, Inc.
    Inventor: Scott L. Harbeson